Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows.

RCT Entities:   Population Interventions Outcomes

Correction

Following publication of the original article [1], the authors reported errors in the formatting of the table. The details of the errors are as follows:

In Table 1, the data presented do not correspond to the row title:

The education row currently contains incorrect data.

The weight row currently contains the years of education.

The APOEε4 genotype row currently contains the weight data.

In Table 1, the data should be displayed as follows:

Variable

Intention-to-treat population (n = 797)

Placebo

(n = 266)

Gantenerumab

105 mg

(n = 271)

Gantenerumab

225 mg

(n = 260)

Age, years, mean (SD)

69.5 (7.5)

70.3 (7.0)

71.3 (7.1)

Education, years, mean (SD)

12.6 (4.3)

12.9 (4.8)

12.1 (4.5)

Weight, kg, mean (SD)

69.8 (12.9)

70.5 (13.6)

70.1 (12.5)

APOEε4 genotype, %a